Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of July. The chart below provides highlights of key monograph updates made this month (not an inclusive list).
Click on the name of the drugs to view the full monographs on eMPR.com.
Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change
| DRUG NAME | UPDATES | |||||||
| (Click on drug name to go to MPR monograph.) | IND | D | CON | W/P | ITX | ADR | HS | MFR |
| APOKYN (Apomorphine HCl) | X | X | X | |||||
| BELBUCA (Buprenorphine) | X | X | X | |||||
| BEOVU (Brolucizumab-dbll) | X | X | X | |||||
| EVRYSDI (Risdiplam) | X | X | X | |||||
| KRYSTEXXA (Pegloticase) | X | X | X | X | ||||
| LANTUS (Insulin glargine) | X | X | X | X | |
X | ||
| LOPRESSOR HCT (Metoprolol tartrate, hydrochlorothiazide) | X | X | X | X | ||||
| NAROPIN (Ropivacaine HCl) | X | X | X | X | ||||
| QSYMIA (Phentermine HCl/topiramate ext-rel) | X | X | X | X | X | |||
| SOLIQUA 100/33 (Insulin glargine, lixisenatide) | X | X | X | X | ||||
| Review more drug monograph updates |
